- Home
- ZIONO vs SNN Comparison
ZIONO vs SNN Comparison
Compare ZIONO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIONO
- SNN
- Stock Information
- Founded
- ZIONO N/A
- SNN 1856
- Country
- ZIONO United States
- SNN United Kingdom
- Employees
- ZIONO 9679
- SNN N/A
- Industry
- ZIONO Major Banks
- SNN Industrial Specialties
- Sector
- ZIONO Finance
- SNN Health Care
- Exchange
- ZIONO Nasdaq
- SNN Nasdaq
- Market Cap
- ZIONO N/A
- SNN 12.4B
- IPO Year
- ZIONO N/A
- SNN 1999
- Fundamental
- Price
- ZIONO $26.39
- SNN $29.44
- Analyst Decision
- ZIONO
- SNN Strong Buy
- Analyst Count
- ZIONO 0
- SNN 1
- Target Price
- ZIONO N/A
- SNN N/A
- AVG Volume (30 Days)
- ZIONO N/A
- SNN 674.7K
- Earning Date
- ZIONO N/A
- SNN 08-01-2024
- Dividend Yield
- ZIONO N/A
- SNN 2.55%
- EPS Growth
- ZIONO N/A
- SNN 39.77
- EPS
- ZIONO N/A
- SNN 0.35
- Revenue
- ZIONO N/A
- SNN $5,642,000,000.00
- Revenue This Year
- ZIONO N/A
- SNN $6.92
- Revenue Next Year
- ZIONO N/A
- SNN $5.43
- P/E Ratio
- ZIONO N/A
- SNN $41.81
- Revenue Growth
- ZIONO N/A
- SNN 5.48
- 52 Week Low
- ZIONO N/A
- SNN $21.53
- 52 Week High
- ZIONO N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- ZIONO 52.08
- SNN 46.87
- Support Level
- ZIONO $26.71
- SNN $28.26
- Resistance Level
- ZIONO $27.01
- SNN $29.64
- Average True Range (ATR)
- ZIONO 0.19
- SNN 0.36
- MACD
- ZIONO -0.03
- SNN 0.05
- Stochastic Oscillator
- ZIONO 21.25
- SNN 58.65
About ZIONO Zions Bancorporation N.A. Dep Shs Repstg 1/40th Perp Pfd Ser G
Zions Bancorporation is a regional U.S. bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.